The CHEUAL Breast Cancer Model Application – Interactive Cost-Utility Analysis of Bevacizumab plus Paclitaxel in Metastatic BC to Support Decision-Making: A Portuguese clinical perspective

Abstract

Breast cancer is associated with a high prevalence, incidence and mortality all over the world (of 0,83%, 0,07% and 0,028% of Portuguese female population, respectively, WHO - Globocan 2008 and HEO 2008), representing a huge burden on individuals and health systems. The CHEUAL BC model is an economic evaluation interactive tool that makes inferences about future direct costs and health outcomes, providing an Incremental Cost per QualityAdjusted Life Year (QALY) Ratio, capable of supporting clinical, hospital formulary drug inclusion and reimbursement decisionmaking, allowing the identification of breast cancer management strategies and treatments that are good value for money in a transparent and efficient way, in real time. Objective To evaluate the cost-utility of a new treatment option for metastatic breast cancer, Bevacizumab in association with Paclitaxel (still in Stage IV in Portugal), from the Portuguese clinical perspective, for better BC management.